Javier Merino Alonso, Fernando Piedra Sánchez, M. A. Velaz Suárez, R. Luque Infante, A. Barrio Gil-Fournier
Objective: To determine the variability of chemotherapy schemes used in the treatment of ovarian cancer. Method: In 10 Spanish hospitals, the chemotherapy schemes usually prescribed for the treatment of ovarian cancer were recorded. It was considered the variability, any difference in the cytostatics' dosage or their order of administration. Results: 56 records were obtained. For each scheme, it was calculated the variability index according to the equation: no. variations-1/total no. of scheme records × 100. The following results were obtained: paclitaxel + carboplatin (36.4%), paclitaxel + cisplatin (66.7%), liposomal doxorubicin (37.5%), topotecan (14.3%), cyclophosphamide + cisplatin (50%), monotherapy paclitaxel, monotherapy paclitaxel (66.7%) and gemcitabine (0%). Conclusions: The observed high variability implies that the selection criteria for each scheme differ among hospitals. It is necessary a systematic revision of the scientific literature and a consensus among oncologists in order to establish a reference treatment for every studied scheme, based on efficacy and safety data
© 2001-2024 Fundación Dialnet · Todos los derechos reservados